Investigating a new target for treating acute myeloid leukemia
Adhesion GPCR regulation of acute myeloid leukemia stem cells - Resubmission - 1
This study is looking at a protein called CD97 to see how it influences leukemia stem cells in acute myeloid leukemia (AML), with the hope of creating new treatments that can better fight the disease and prevent it from coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11042155 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific protein, CD97, affects leukemia stem cells in acute myeloid leukemia (AML). By targeting CD97, the researchers aim to develop new therapies that can effectively eliminate these resistant cells, which are responsible for the recurrence of AML after treatment. The study involves analyzing the role of CD97 in leukemia cell growth and survival, as well as its potential as a therapeutic target. Patients may benefit from innovative treatments that specifically target the underlying causes of their disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute myeloid leukemia, particularly those who have not responded well to existing therapies.
Not a fit: Patients with other types of leukemia or those who have already achieved remission may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for acute myeloid leukemia, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting similar proteins in leukemia, suggesting that this approach could be effective.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Park, Christopher Y — New York University School of Medicine
- Study coordinator: Park, Christopher Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.